The British Journal of Psychiatry
Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study.
I Pelc, P Verbanck, O Le Bon, M Gavrilovic, K Lion, P Lehert

Abstract

BACKGROUND Acamprosate is a newly registered drug that appears to reduce alcohol-drinking in both animal models and clinical conditions.

METHOD In order to assess the efficacy and safety of the drug in the treatment of detoxified alcoholics, we performed a 90-day double-blind trial comparing two dosages of acamprosate (1332 mg/day and 1998 mg/day).

RESULTS For all efficacy parameters, acamprosate appeared to be significantly superior to placebo, with a trend towards a better effect at the higher dosage. Furthermore, acamprosate appeared to be extremely safe.

CONCLUSION This study confirms that acamprosate could be an interesting adjuvant for maintaining abstinence in detoxified alcoholics.